Solid Biosciences to Present at Barclays Global Healthcare Conference
Solid Biosciences Inc. (Nasdaq: SLDB) announced that its CEO Bo Cumbo will present at the Barclays Global Healthcare Conference on March 14, 2023, at 3:35 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Solid Biosciences Inc. (Nasdaq: SLDB) announced that its CEO Bo Cumbo will present at the Barclays Global Healthcare Conference on March 14, 2023, at 3:35 PM ET. A live webcast will be accessible on the Company's website, with a replay available post-event.
Institutional investors can contact their Barclays representative for potential meetings with management during the conference.
Solid Biosciences is committed to advancing genetic medicines for neuromuscular and cardiac diseases, including therapies for Duchenne and Friedreich’s Ataxia.
Details
News Market Reaction – SLDB
The recorded move for SLDB in the trading session of this news was +5.01%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHARLESTOWN, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2023, at 3:35 PM ET.
A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A replay will be available on the Company’s website following the event.
Institutional investors interested in meeting with management during the conference may reach out to their Barclays representative.
About Solid Biosciences
Solid Biosciences is a life science company focused on advancing a portfolio of neuromuscular and cardiac programs, including SGT-003, a differentiated gene transfer candidate for the treatment of Duchenne, AVB-202-TT, a gene transfer candidate for the treatment of Friedreich’s Ataxia, AVB-401 for BAG3 mediated dilated cardiomyopathy, and additional assets for the treatment of undisclosed cardiac diseases. Solid aims to be the center of excellence, bringing together those with expertise in science, technology, disease management and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com
Solid Biosciences Media Contact:
Tim Palmer
Senior Manager, Corporate Communications
607-760-4223
Tim@solidbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.